Forced Expiratory Volume in 1 Second and Cognitive Aging in Men by Weuve, Jennifer et al.
Forced Expiratory Volume in 1 Second and Cognitive
Aging in Men
Jennifer Weuve, ScD,w M. Maria Glymour, ScD,z Howard Hu, MD, ScD,§ David Sparrow, DSc,k#
Avron Spiro III, PhD,ww Pantel S. Vokonas, MD,k# and Augusto A. Litonjua, MDz z§§
OBJECTIVES: To evaluate forced expiratory volume in 1
second (FEV1, a measure of overall lung function), long-
term average FEV1, and rate of decline in FEV1 in relation
to cognition and cognitive decline in older men.
DESIGN: Prospective observational study.
SETTING: Community-based population.
PARTICIPANTS: Eight hundred sixty-four older men from
the Normative Aging Study.
MEASUREMENTS: Starting in 1984, participants under-
went triennial clinical evaluations. Lung function assess-
ments provided estimates of FEV1. Cognitive assessments
entailing tests of several cognitive abilities began in 1993.
FEV1 measured approximately 12 years before baseline
cognitive testing, average FEV1 over the 12-year period,
and rate of change in FEV1 were all evaluated in relation to
baseline and change in performance on the cognitive tests.
RESULTS: In multivariable-adjusted analyses, associa-
tions between FEV1 and baseline cognitive scores were
mixed, although average FEV1 predicted significantly better
performance on tests of visuospatial ability (P 5.04) and
general cognition (P 5.03). Higher FEV1 was more consis-
tently associated with slower cognitive decline, but only the
association between historical FEV1 and attention was sig-
nificant (difference per standard deviation in FEV1 5 0.056,
P 5.05). Rate of FEV1 decline was not consistently asso-
ciated with cognitive function or decline. Findings were
generally similar or stronger in men who had never smoked.
To account for potential bias due to selective attrition,
inverse probability of censoring weights were applied to the
cognitive decline analyses, yielding slightly larger estimates;
the inadequate prognostic power of the censoring models
limited this approach.
CONCLUSION: Overall, the data provide limited evi-
dence of an inverse association between FEV1 and cognitive
aging. J Am Geriatr Soc 59:1283–1292, 2011.
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Despite the tremendous public health importance ofcognitive impairment and decline in older adult-
hood,1–8 few modifiable risk factors have been identified.
Respiratory function is of particular interest as a po-
tential risk factor because it is potentially modifiable by
individual behavior interventions (e.g., smoking cessation9
and pulmonary rehabilitation10) or policy changes (e.g., air
pollution reduction11). A large body of evidence suggests
that poor lung function is related to impaired cognition12–23
and adverse findings on brain imaging,21,24 but most large-
scale studies have been cross-sectional, with only limited
evidence indicating that better lung function corresponds to
slower cognitive decline.17,20 Moreover, studies of cognitive
change have used lung function measured on a single day.
Such single assessments may be subject to considerable
measurement error or random fluctuation, possibly reduc-
ing the ability to identify an association between long-term
lung function and cognitive change. Furthermore, no study
has examined the association between changes in lung
function and cognitive aging, although change in function is
arguably more clinically relevant than lung function at a
single time point. In a large cohort of older men, this study
assessed whether historical, long-term average, or change in
forced expiratory volume in 1 second (FEV1), a measure of
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overall lung function, predicted cognitive function or cog-
nitive changeFmeasures of cognitive aging.
METHODS
Study Population
Participants were from the Normative Aging Study (NAS),
a longitudinal study of aging established in 1963 by the
Department of Veterans Affairs (VA) and based at the Bos-
ton VA Medical Center.25 The study enrolled 2,280 men
from the Greater Boston area who were aged 21 to 80 and
free of known chronic medical conditions, including
chronic lung disease, asthma, coronary heart disease, high
blood pressure, diabetes mellitus, and cancer. The men have
undergone detailed clinical evaluations at 5-year intervals
for those younger than 52 years old and at 3-year intervals
for those aged 52 and older; since 1984, evaluations have
occurred at 3-year intervals for all participants. These eval-
uations have entailed the collection of medical history in-
formation, physical examinations, laboratory tests, and
completion of questionnaires on smoking history, education
level, and other factors that may influence health. Annual
attrition from all causes has been less than 1%, and more
than 80% have responded to mailed questionnaires sup-
plementing on-site examinations. Altogether, 864 men with
appropriate data on FEV1 and cognitive function contrib-
uted to the analyses.
Assessment of Pulmonary Function
Since 1984, participants have provided information on re-
spiratory symptoms and undergone airway responsiveness
tests; 1,296 men are included in this cohort. A trained
technician measured each participant’s lung function using
spirometry according to the standardized protocols of the
American Thoracic Society (ATS).26 FEV1 measurements
were obtained using standard techniques.27 Spirometry was
performed in the standing position using a nose clip, a 10-L
water-filled survey recording spirometer, and an Eagle II
minicomputer (Warren E. Collins, Braintree, MA). Spi-
rometry was repeated for up to a maximum of eight spiro-
grams, so that at least three acceptable spirograms were
obtained, at least two of which were reproducible with
FEV1 measurements within 5% of each spirogram. Accept-
ability of the spirograms was judged according to the ATS
standards.26
Several aspects of FEV1 were evaluated in the analyses.
The prospective association between FEV1 and cognitive
function was characterized by examining FEV1 measured a
median of 12 years (range 7–22 years;  4 study cycles)
before baseline cognitive testing, generally the oldest mea-
surement available. This measure is called ‘‘historical
FEV1.’’ Annual rate of change in FEV1 up through baseline
cognitive testing (up to 2 years after) was also explored.
Finally, the possibility that ‘‘usual FEV1’’ may be relevant to
cognitive aging was considered, and although historical
FEV1 is an indicator of ‘‘usual FEV1,’’ the average of re-
peated FEV1 measurements is a more-precise indicator, be-
cause FEV1 measurements tend to be correlated over time
(Spearman correlation 5 0.74–0.90 between the first and
fifth measurements). Because the number of available mea-
sures of FEV1 differed from person to person, a mixed
model framework was used to estimate long-term average
and rate of change in FEV1 (described further below).
Assessment of Cognitive Function
Cognitive assessments began in 1993. The battery of
cognitive tests included measures of sustained attention,
perceptual speed, memory, language, visuomotor ability,
and global cognition. These tests were taken from several
different batteries, including the Neurobehavioral Evalua-
tion System 2 (NES2),28 the Wechsler Adult Intelligence
ScaleFRevised (WAIS-R),29 the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) battery,30 and
the developmental test of visual-motor integration (VMI).31
The following tests were administered to participants:
Mini-Mental State Examination (MMSE);32 continuous
performance, pattern memory, and pattern comparison
(NES2); vocabulary and digit span backwards (WAIS-R);
and the Boston naming test, word list memory, delayed
word list recall, and verbal fluency (CERAD); and con-
structional praxis (copying of figures taken from CERAD,
VMI, and MMSE). Cognitive examinations were approx-
imately 3.1 years apart. The composition of the battery
changed somewhat over the course of the study (e.g., some
tests were administered at only one study cycle), resulting in
variable sample sizes and number of repeated assessments
for each individual test.
FEV1 was evaluated in relation to baseline cognitive
test score and change in cognitive test score over three cycles
of testing.
The Human Subjects Committee of the Boston VA
Medical Center and the institutional review board of the
Brigham and Women’s Hospital approved this research.
Statistical Analysis
Descriptive Analyses
To inform decisions about the approach for modeling ex-
posures and the responses in the association models, the
distributions of all FEV1, cognitive function and covariate
variables were examined, and means and frequencies of
important covariates were computed, testing differences
across age- and height-adjusted quartiles of FEV1 using
F tests (for continuous variables) and likelihood ratio
chi-square tests (for categorical variables). These particular
analyses used the data from the analyses of average FEV1
and baseline MMSE, a global cognition test.
Average FEV1 and Annual Rate of Change in FEV1
Each participant’s long-term average FEV1 was estimated
using a linear mixed-effects model, regressing the repeated
FEV1 measurements (2–5 per person) on an intercept so that
average FEV1 was the sum of the fixed intercept (overall
average) and the participant’s random intercept coefficient.
A linear mixed effects model was also used to estimate
annual change in FEV1, regressing the repeated FEV1 mea-
surements on time. The annual rate of change in FEV1 for a
given participant was estimated as the sum of the fixed
effect for time and his random slope coefficient for time.
The use of linear mixed-effects models for both of these
estimates accommodated the variability in the timing and
number of FEV1 measurements for each participant.
33
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Association Between FEV1 Measures and Baseline
Cognitive Function
Generalized estimating equation (GEE) models were used
to estimate the association between each FEV1 measure and
each cognitive score when it was first administered. For
most models, the identity link was used, a normal response
distribution was assumed, and then the mean difference in
cognitive score per standard deviation (SD) increment in
FEV1 measurement was estimated. Scores on some cogni-
tive tests did not follow a normal distribution. The MMSE
and number of correct responses on the pattern comparison
test were converted to error counts, and log-link GEE mod-
els assuming a negative binomial response distribution were
used. The regression coefficients thus estimate percentage
difference in error counts per SD increment in FEV1
measurement. Because of an extreme ceiling evident in the
distribution of scores on the Boston naming test, the prob-
ability of committing at least one error (vs none) on this test
was analyzed.
Association Between FEV1 Measures and Change in
Cognitive Function
Similar to the approach for analyzing baseline cognitive
function, GEE regression models were used to estimate the
association between each FEV1 measure and change in
cognitive score over up to three testing cycles. Terms were
included in these models for time and the cross-product of
time and FEV1 measurement. These cross-product terms
indicated the difference in cognitive score trajectories across
FEV1 level. The timing of the cognitive examinations did
not deviate substantially from 3.1-year intervals, so time
was modeled as an ordinal variable marking the baseline,
second, and third examination cycles. Some tests were in-
troduced to or dropped from the cognitive battery over
time, which was accounted for by shifting the ‘‘baseline’’
cycle for some tests to correspond to the first time the par-
ticipant took the test.
All analyses were adjusted for age at baseline cognitive
assessment, time between the lung and baseline cognitive
assessment, years of education, computer experience at the
time of the cognitive test, smoking status (never, former, or
current), pack-years of smoking, and height (shorter per-
sons have smaller lung volumes and, in previous studies,
have performed more poorly on cognitive tests in older
adulthood34,35). For analyses of cognitive change, cross-
products between the time variables and age and education
were included. For analyses of average FEV1 and change in
FEV1, the span of time covered by the lung assessments was
also included in the model.
Reporting Framework
To promote comparability of the findings, they are reported
as associations per 6.5-dL increment in FEV1, which is the
approximate SD of FEV1 measurements in the analyses of
historical FEV1. For annual rate of change in FEV1, asso-
ciations per SD in decline of FEV1 are reported (0.3 dL/y).
The normally distributed cognitive scores were transformed
into z scores, using the scores’ respective means and SDs at
baseline. This transformationFby homogenizing the
scores’ units of measurementFfacilitates the comparison
of findings from the analyses of these scores.
Secondary Analyses
Several secondary analyses were conducted. First, inade-
quately measured smoking history could influence any ob-
served association between the FEV1 measures and the
cognitive outcomes. Thus, all analyses were repeated
restricting data to never smokers. Second, as with many
studies of aging, there was concern that differential survival
to participate in the cognitive study and differential loss to
follow-up over the course of the study could bias the find-
ings on cognitive change.36 Analyses restricted to never
smokers partially address this problem, because never
smokers have lower mortality rates. To further probe the
potential effect of differential loss to follow-up over the
course of the study, inverse probability of noncensoring
weights (IPCW) were applied to the data, in which the
weights were based on logit models of not being censored
(i.e., continuing in the study) from one cycle to the next.37
These models concern prediction of loss to follow-up,
rather than cognitive decline, allowing great flexibility in
covariates that they include. The final models of not being
censored included diabetes mellitus, fasting blood glucose,
white blood cell count, hemoglobin, previous cognitive
score, and age-squared, in addition to the variables that
were already being used in the analytical models.
For all of the analyses, Po.05 was used as the level of
statistical significance.
RESULTS
In the exploration of the men’s characteristics across quar-
tiles of age- and height-adjusted long-term average FEV1,
those with higher FEV1 were significantly less likely to have
been current or former smokers (Table 1), and in men who
had ever smoked, pack-years of smoking corresponded to
lower FEV1. In these analyses not adjusted for other co-
variates, the number of errors on the MMSE, a measure of
global cognition, was approximately 12% lower in men in
the highest quartile of average FEV1 (P 5.08) than in men in
the lowest quartile. Of these men who had multiple re-
peated FEV1 measurements, nearly all experienced a decline
in their FEV1 over the course of follow-up (median rate of
decline 0.13 dL/y, interquartile range 0.11–0.15 dL/y).
Rates of FEV1 decline were significantly faster in men
who were older at first measurement. FEV1 also declined
significantly faster in former smokers than in never smokers
and declined faster still in current smokers; in ever smokers,
pack-years of smoking was associated with significantly
faster decline. In unadjusted analyses, the number of errors
on the MMSE was greater in men in the second, third, and
highest quartile of rate of FEV1 decline than in men in the
lowest quartile (8.7%, 23.9%, and 27.2%, respectively;
P 5.003).
The multivariable-adjusted associations between the
FEV1 measures and cognitive test scores at baseline were
somewhat mixed, although the largest and most statistically
significant findings were those that indicated better cogni-
tive function with higher FEV1 (Figure 1, Table 2). For in-
stance, men with higher average FEV1 performed
significantly better on two measures of visuospatial abil-
ity: constructional praxis (Figure 1) and errors on the test of
pattern comparison (Table 2). A similar albeit weaker pat-
tern was evident for historical FEV1. Errors made on the
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MMSE were significantly less frequent in men with higher
average FEV1 ( 8%/6.5-dL increment in average FEV1)
(Table 2).
The FEV1 measures were generally associated with
slower decline in performance on the cognitive tests
(Figure 2 and Table 2), although the only statistically




























































Immediate word list recall
Delayed word list recall
Pattern memory (response
time)
Pattern memory (# correct)
Vocabulary
Pattern comparison (response time)
Constructional praxis
Difference (95% CI) in baseline standardized cognitive score, per
6.5-deciliter increment in FEV  measured 12 years prior to
baseline cognitive assessment
Difference (95% CI) in baseline standardized cognitive score, per
6.5-deciliter increment in long-term average FEV
Figure 1. Adjusted difference in baseline standardized cognitive score per standard deviation (SD) increment in forced expiratory
volume in 1 second (FEV1). 6.5 dL is the SD of historical FEV1. Analyses adjusted for age, height, education, computer experience,
smoking status, pack-years of smoking, and time between lung function (most recent for average FEV1) and baseline cognitive
assessments. Analyses of average FEV1 additionally adjusted for time span between first and last lung function assessments.
Smaller
values for timed tests indicate better performance, but for comparability with the other test scores, the timed scores were reversed so
that higher values represent better performance. CI 5 confidence interval.
Table 1. Characteristics of Study Participants at Time of Baseline Cognitive Examination, by Quartile of Agew- and
Height-Adjusted Long-Term Average Forced Expiratory Volume in 1 Second (FEV1)
Characteristic
Quartile of Agew- and Height-Adjusted FEV1
P-Value from Test of













Age, mean  SD 68.1  7.2 68.6  7.3 69.3  7.2 68.3  7.3 .28
Education, years, mean  SD 13.8  2.6 14.4  2.6 14.3  2.6 14.4  2.6 .07
Previous computer experience, % 40.6 39.0 38.0 39.7 4.99
Smoking status, % o.001
Current 12.9 5.5 3.8 2.8
Former 73.7 63.8 62.9 60.8
Never 13.4 30.7 33.3 36.5
Pack-years (in ever smokers), mean  SD 40.5  26.2 31.7  21.1 26.5  20.8 17.3  17.1 o.001
Baseline MMSE score: relative error count ref 6.7%  5.1%  12.0% .06
Corresponds to analyses of average FEV1 and Mini-Mental State Examination (MMSE).
wAge as of participants’ first FEV1 measurement.
SD 5 standard deviation.
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significant association was between historical FEV1 and
slower decline in the longest digit span recalled. Modest but
not statistically significant associations (.05oPo1.0) were
also observed between historical FEV1 and slower decline
on the test of delayed word list recall, as well as between
average FEV1 and response time on the test of pattern
comparison.
Annual rate of decline in FEV1 was not consistently
associated with baseline or change in performance on the
cognitive tests (Figure 3 and Table 2). The largest associ-
ations, observed between rate of decline in FEV1 and worse
performance on the number of digit spans recalled (P 5.07)
and immediate word list recall (P 5.08) at baseline testing,
were modest and not statistically significant.
The secondary analyses provided some support for
the findings. In never smokers, associations between aver-
age FEV1 and cognitive decline were generally much
larger in magnitude than in the overall study population
(Supplementary Table S1). In particular, never smokers with
higher FEV1 had significantly slower decline than those
with lower FEV1 in the constructional praxis test and
errors committed on the pattern comparison test, both of
which assess visuospatial ability (P 5.05 for both out-
comes; error count data not shown in Table). In never
smokers, rate of FEV1 decline was more uniformly
associated with worse cognitive decline than in the overall
study population, but none of these findings was signi-
ficant. By contrast, in former smokers, average FEV1 and
rate of FEV1 decline did not predict worsening cognitive
decline.
For the IPCW models of censoring, it was possible to
identify variables that were strongly associated with cen-
soring, although the models themselves did not fit the data
well (e.g., a typical pseudo-R-squared for a model was
0.05). Weighted analyses produced results indicating
slightly stronger associations between higher FEV1 and
slower cognitive decline, particularly with respect to FEV1
measures in association with decline on delayed word list
recall and pattern comparison response time (e.g., estimate
shifted by 25% for average FEV1 and pattern comparison;
data not shown).
DISCUSSION
The results from this study of 864 men, many who were
middle-aged at the time of their initial lung function assess-
ments, suggest that lung function, as indicated by prospec-
tively measured and long-term average FEV1, may be
modestly associated with slower decline in some cognitive
functions, including working memory and visuospatial abil-
ity. Some significant associations were found between FEV1
and baseline cognitive performanceFincluding performance
on a global test of cognitionFbut these results were less
directionally consistent than the results for cognitive change.
This study is the first, to the knowledge of the authors, to
report on decline in FEV1 in relation to cognitive aging; little













































Difference (95% CI) in change in standardized cognitive score, per
6.5-deciliter increment in FEV  measured 12 years prior to
baseline cognitive assessment
Difference (95% CI) in change in standardized cognitive score, per
6.5-deciliter increment in long-term average FEV
Figure 2. Adjusted difference in baseline standardized cognitive score per standard deviation (SD) increment in forced expiratory
volume in 1 second (FEV1). 6.5 dL is the SD of historical FEV1. Analyses adjusted for age, height, education, computer experience,
smoking status, pack-years of smoking, and time between lung function (most recent for average FEV1) and baseline cognitive
assessments. Analyses of average FEV1 additionally adjusted for time span between first and last lung function assessments.
Smaller
values for timed tests indicate better performance, but for comparability with the other test scores, the timed scores were reversed so
that higher values represent better performance. CI 5 confidence interval.
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evidence was found of an association between rate of decline
in FEV1 over the past 12 years and subsequent cognitive
performance and decline in cognitive function.
Although some of these findings are suggestive, they are
not inconsistent with a null association between FEV1 and
cognitive decline. The associations were generally not sta-
tistically significant. Moreover, results for long-term aver-
age FEV1 were not consistently stronger than those for
historical FEV1. If usual FEV1 and cognitive decline were
related, then the use of long-term average FEV1Fa more-
precise measure of usual FEV1 than the single historical
measurement of FEV1Fwould yield, in theory, somewhat
‘‘deattenuated’’ estimates of association.38 Nonetheless, re-
sults were often stronger in men who had never smoked,
suggesting that cigarette smoking history may account for
some of the link between FEV1 cognitive decline by con-
founding the association or, as described below, as a deter-
minant of selection into the study. The results from the
IPCW analyses provided suggestive yet weak evidence in
this regard.
The hypothesized relationship between lung function
and cognitive aging has several compelling biological mech-
anisms. Poor lung function and lung injury, or their triggers,
may initiate an inflammatory response.39,40 The ensuing
inflammation may evolve into low-grade systemic inflam-
mation, which in turn may invoke an adverse vascular re-
sponse and additional oxidative stress.41 Although evidence
of the neurocognitive effects of vascular inflammation re-
mains limited, inflammation and oxidative stress in the
central nervous system (CNS) appear to have roles in the
pathogenesis of dementia.42 Impaired lung function is also
associated with a procoagulant state,43,44 which increases
the risk of cerebrovascular injury and stroke. Several epi-
demiological studies have found prospective associations
between low FEV1 and greater stroke risk.
45–47 Nonethe-
less, mixed findings have emerged from studies that have
evaluated FEV1 in relation to imaging-based measures of
cerebrovascular injury.21,24,48 In one study, lower FEV1 was
associated with significantly higher risks of high white
matter lesion grade and cerebral infarcts, even in nonsmok-
ers.24 By contrast, comparable findings from other studies
diminished substantially upon further adjustments for
smoking and other covariates.21,48 Finally, it is possible
that impairment in lung function may cause episodes of
mild hypoxia, resulting in transient deficits in the metab-
olism of central nervous system neurotransmitters,49 but
ventilatory function measures such as FEV1 are not good
indices of gas exchange and vascular oxygenation, so stud-





































Immediate word list recall
Delayed word list recall
Pattern memory (response
time)
Pattern memory (# correct)
Vocabulary
Pattern comparison (response time)
Constructional praxis

















Difference (95% CI) in baseline standardized cognitive score, per
0.3 deciliter/year increment in rate of FEV  decline
Difference (95% CI) in change in standardized cognitive score, per
0.3 deciliter/year increment in rate of FEV  decline
Figure 3. Adjusted difference in baseline standardized cognitive score per standard deviation (SD) increment in rate of decline in
forced expiratory volume in 1 second (FEV1). 0.3 dL/y is the SD of the rate of FEV1 decline. Analyses adjusted for age, height,
education, computer experience, smoking status, pack-years of smoking, time between lung function (most recent) and baseline
cognitive assessment, and time span between first and last lung function assessments. Smaller values for timed tests indicate better
performance, but for comparability with the other test scores, the timed scores were reversed so that higher values represent better
performance. CI 5 confidence interval.
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Numerous cross-sectional studies of FEV1 and cogni-
tive performance have been conducted, many of which
found strong associations between the two,12–21,23 but
some of these studies did not account in detail for poten-
tially important sources of confounding, including age, ed-
ucation, height, and smoking history, which may have
resulted in higher estimates. Fewer studies, by contrast,
have examined FEV1 in prospective relation to cognitive
function, although they have observed similarly protective
associations.19,20,22 For example, in 3,036 men participat-
ing in the Honolulu Heart Program, higher FEV1, measured
when they were aged 53 on average, was associated with
significantly better performance on a test of general cogni-
tion administered 23 years later.22 Likewise, in the Medical
Research Council (MRC) National Survey of Health and
Development (NSHD), FEV1, measured in 1,778 43-year-
old adults, was associated with better performance 10 years
later on a test of verbal ability.20 A smaller study of twins
(N 5 444) aged 40 to 84 found that higher FEV1 predicted
better performance 6 years later on tests of perceptual speed
and visuospatial ability but not on a test of attention, even
though FEV1 was cross-sectionally associated with perfor-
mance on all tests.19 In the current study, measures of cognitive
function were not consistently associated with FEV1 measured
12 years earlier; only performance on a test of visuospatial
ability was markedly better with higher historical FEV1.
Studies of lung function in relation to cognitive decline
have been even rarer, and their findings have been
mixed.17,20 Of 1,011 participants aged 70 to 80 in the
Established Populations for Epidemiologic Studies of the
Elderly (EPESE), higher baseline peak expiratory flow rate
(PEFR) corresponded to less decline over a 2.5-year period
in a global measure of cognition,17 yet in the MRC NSHD
study, baseline FEV1 predicted significantly less decline over
the ensuing 10 years on a test of perceptual speed but not on
a test of verbal memory.20 Although the current study found
less cognitive decline with higher levels of FEV1, the asso-
ciation was significant only with respect to FEV1 measured
12 years before baseline cognitive testing and 9-year decline
in working memory and attention.
No consistent association was found between rate of
decline in FEV1 and cognitive function or decline. It may be
that absolute FEV1 is more important than decline or that
the rates of FEV1 decline that the men in this study expe-
rienced were slow enough to permit adequate neurocogni-
tive adaptation.
This study has limitations that warrant mention. First,
factors that were not assessed or were mismeasured may
have confounded the estimates that suggest cognitive ben-
efit with higher FEV1. In particular, this study did not ac-
count for participants’ engagement in physical activity, an
independent predictor of FEV1 in some studies (e.g., Jakes
et al.50) and of cognitive function and decline,51 although
the findings were adjusted for several other potential con-
founding variables, including some that typically correlate
strongly with engagement in physical activity. By contrast,
this study offers careful consideration of smoking history. In
particular, sensitivity analyses restricted to never smokers
circumvented some of the challenges associated with mea-
suring smoking exposure dose and with the complex rela-
tionship between smoking history, lung function, and
cognitive decline.
The suggestive but generally statistically nonsignificant
findings related to FEV1 and cognitive decline were consistent
with those from the EPESE and MRC NSHD cohorts,17,20
but the current analyses may have been underpowered, given
that they included fewer individuals. Nevertheless, many of
this study’s cross-sectional analyses entailed sample sizes that
were at least as large as those from other cross-sectional
studies that found significant associations. Moreover, previ-
ous work in the NAS has identified risk factors significantly
associated with cognition and cognitive decline (e.g.,
Weisskopf et al.52, Tucker et al.53), supporting the ability to
identify predictors of cognitive aging in these data.
It is possible that continuation in the study, from initial
lung function testing to subsequent baseline cognitive test-
ing and then to follow-up cognitive testing, varied accord-
ing FEV1 and cognitive trajectory. Specifically, there was
concern that participants with higher FEV1, better baseline
cognitive function, and less cognitive decline would be less
likely to drop out of the study for any reason. The ensuing
bias in the estimates would be downward, in that any ben-
efit of FEV1 on cognitive aging would be underestimated.
This possibility was evaluated by constructing predictive
models of continuation and computing analytical weights
based on these models. FEV1 and prior cognitive function
were generally weak predictors of continuation in the study
after baseline cognitive assessment. These continuation
models, overall, did not provide good fits to the patterns
of continuation in the data, and thus, with a few exceptions,
the results from the IPCW analyses were only slightly
stronger than those from the conventional analyses.
Moreover, this IPCW approach did not address loss to
follow-up from first FEV1 assessment to baseline cognitive
assessment. By contrast, the findings for cognitive decline in
never smokers, in whom it was believed that these differ-
ential patterns of continuation would be less problematic,
were generally stronger in magnitude than those in the
complete cohort.
In summary, these findings provide limited support for
an inverse association between FEV1 and cognitive aging in
men. In contrast, in this first evaluation of long-term decline
in FEV1 and cognitive aging, no clear association was found
between the two.
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